Patents by Inventor Marcel Rozencweig
Marcel Rozencweig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9844593Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.Type: GrantFiled: November 22, 2011Date of Patent: December 19, 2017Assignee: INNATE PHARMA SAInventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier
-
Publication number: 20150250723Abstract: The present invention relates to a method for treating triple-negative metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises nonpegylated liposomal doxorubicin, a taxane and a chemotherapeutic agent selected from the group consisting of capecitabine, vinorelbine, gemcitahine, carboplatin, and ixahepilone, and wherein said individual previously has been administered an anthracycline. In some embodiments, the individual is not administered transtuzumab.Type: ApplicationFiled: September 5, 2013Publication date: September 10, 2015Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
-
Publication number: 20130251711Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.Type: ApplicationFiled: November 22, 2011Publication date: September 26, 2013Applicant: INNATE PHARMA SAInventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier
-
Publication number: 20110256215Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.Type: ApplicationFiled: June 29, 2011Publication date: October 20, 2011Applicant: SOPHERION THERAPEUTICS LLCInventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
-
Patent number: 8026267Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.Type: GrantFiled: September 10, 2010Date of Patent: September 27, 2011Assignee: Sopherion Therapeutics, LLCInventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
-
Publication number: 20100323004Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.Type: ApplicationFiled: September 10, 2010Publication date: December 23, 2010Applicant: SOPHERION THERAPEUTICS LLCInventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
-
Publication number: 20100260831Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Inventors: Marcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
-
Publication number: 20090325913Abstract: The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the treatment of pain associated with metastatic hormone refractory prostate cancer.Type: ApplicationFiled: September 24, 2007Publication date: December 31, 2009Inventors: Thomas J. McKearn, Marcel Rozencweig
-
Publication number: 20090312295Abstract: The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2nd line treatment of metastatic hormone refractory prostate cancer.Type: ApplicationFiled: September 24, 2007Publication date: December 17, 2009Inventors: Thomas J. McKearn, Marcel Rozencweig
-
Patent number: 6414014Abstract: Taxol dosages of about 135 mg/m2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H2-receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m2 and about 175 mg/m2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.Type: GrantFiled: February 7, 2000Date of Patent: July 2, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Renzo Mauro Canetta, Elizabeth Eisenhauer, Marcel Rozencweig
-
Patent number: 5670537Abstract: Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses.Type: GrantFiled: September 19, 1996Date of Patent: September 23, 1997Assignee: Bristol-Meyers Squibb CompanyInventors: Renzo Mauro Canetta, Elizabeth Eisenhauer, Marcel Rozencweig
-
Patent number: 5665761Abstract: Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses.Type: GrantFiled: November 22, 1996Date of Patent: September 9, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Renzo Mauro Canetta, Elizabeth Eisenhauer, Marcel Rozencweig
-
Patent number: 5641803Abstract: Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following protreatment to minimize hypersensitivity responses.Type: GrantFiled: October 18, 1995Date of Patent: June 24, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Renzo Mauro Carretta, Elizabeth Eisenhauer, Marcel Rozencweig
-
Patent number: 5621001Abstract: Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses.Type: GrantFiled: November 20, 1995Date of Patent: April 15, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Renzo M. Canetta, Elizabeth Eisenhauer, Marcel Rozencweig